The effects of probiotics on risk and time preferences Research Published on 2022-07-152022-10-05 Journal: Scientific Reports [Category] 유전자 메커니즘, [키워드] Affect animal brain region cognitive conducted creating daily dose double-blinded Effect emotional experimental evidence functional gut microbiota healthy Human increase in Interaction investigated mechanism nervous system participant Placebo placebo-controlled preference risk separated significant decrease the placebo group two group [DOI] 10.1038/s41598-022-16251-x [Article Type] Research
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialClinical Trial Published on 2022-07-082022-10-05 Journal: The Lancet. Respiratory Medicine [Category] 임상, 진단, 치료법, [키워드] 1:1 addition adverse event Analysis assigned baseline Cohort Complete COVID-19 cumulative defined double-blind Europe extracorporeal membrane oxygenation finding Follow-up funding hazard ratio hospital discharge hospitalised hypothesised IMPROVE incidence infused intravenous Invasive mechanical ventilation investigators modified intention-to-treat monoclonal antibody combination Mortality neutralising NIH occurred operation Organ failure outcome participant Patient Phase 3 phase 3 trial Placebo placebo group placebo-controlled trial Primary outcome randomised Randomly receive receiving Registered Remdesivir renal replacement therapy Result Safe seronegative Singapore speed standard care study drug Study participants Support sustained Symptom the placebo group therapy Treatment Uganda USA were excluded with COVID-19 [DOI] 10.1016/S2213-2600(22)00215-6 [Article Type] Clinical Trial
Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response Research Published on 2022-07-082022-10-05 Journal: Scientific Reports [Category] Coronavirus, 임상, [키워드] amplitude baseline candidate change children control groups correlated demonstrated Efficacy ERG evaluate evaluated identify intervals likelihood opposite placebo group placebo-controlled clinical trial placebo-controlled trial positively correlated progression protocol Randomized reduce statistical significance the placebo group Treatment response was measured were measured [DOI] 10.1038/s41598-022-15686-6 [Article Type] Research
ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at RiskACTIVATE-2: 위험에 처한 개인에서 COVID-19에 대한 BCG 백신 접종의 이중 맹검 무작위 시험Randomized Controlled Trial Published on 2022-07-052022-09-12 Journal: Frontiers in Immunology [Category] MERS, 임상, 진단, [키워드] 1:1 95% CI acute respiratory syndrome Against anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies approach Bacillus BCG BCG vaccination benefit clinical criteria Comorbidities controls coronavirus coronavirus disease COVID-19 COVID-19 pandemic develop Diagnosis double-blind trial Efficacy eight elderly vaccination end point evaluated Follow-up Hospitalization Immunity incidence of COVID-19 individual Infection Intervention Laboratory MOST multicenter Occurrence Older participant Patient patients older Placebo positive Randomized recipient reduced reduction respiratory infections Result risk SARS-CoV-2 the placebo group trained immunity Trial vaccination Vaccine Volunteer [DOI] 10.3389/fimmu.2022.873067 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-07-052022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] 1:1 active against addition age Analysis assigned B.1.1.529 baseline Community Complete COVID-19 COVID-19 symptom COVID-19 vaccination COVID-19 vaccine death diagnostic dose double-blind drugs Efficacy Endpoint expected finding follow-up period funding Health healthy Hoffmann-La Roche hospitalised household contact immune response incidence infected individuals Infectious diseases investigator Local monoclonal antibody combination mounted occurred participant patient population Placebo placebo-controlled trial post-hoc post-hoc analysis prespecified analysis prevented prevention of COVID-19 Prophylaxis proportion provided randomisation randomised Randomly receive receiving reduced Regeneron Pharmaceuticals Registered reported risk of COVID-19 risk reduction Romania RT-PCR testing SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected individual Seroconversion seronegative seropositive shown single dose strain stratified subcutaneous injection susceptible symptomatic SARS-CoV-2 infection the placebo group timepoint treatment-emergent adverse event treatment-emergent adverse events uninfected unmet need USA variants waned [DOI] 10.1016/S1473-3099(22)00416-9 [Article Type] Randomized Controlled Trial
Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled TrialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Chest [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 28-day mortality activity acute respiratory symptom adjusted odds ratio adults hospitalized analyzed anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody assigned blinded clinical clinical status clinical trial convalescent plasma convalescent plasma group COVID-19 death died discharged Efficacy groups highest hospital Illness severity improve clinical outcomes lowest multicenter multivariable Neutralizing not differ outcome outcomes passive immunity Patient Placebo placebo group placebo-controlled plasma primary analysis Primary outcome randomization randomized clinical trial randomized patients Randomly receive Registration Regression model Result SARS-CoV-2 SARS-COV-2 infection Secondary analyses selected seronegative seven-category ordinal scale stratified supported the placebo group Treatment treatments for COVID-19 Trial trial participant with COVID-19 [DOI] 10.1016/j.chest.2022.06.029 [Article Type] Randomized Controlled Trial
Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trialRandomized Controlled Trial Published on 2022-07-012022-10-04 Journal: Intensive care medicine [Category] COVID19(2023년), SARS, 임상, [키워드] active smoker Acute respiratory failure Administered Adverse affected artificial assessment assigned Care conducted confidence interval coronavirus disease COVID-19 Critically ill patient daily dose days alive dose double-blind Efficacy and safety event France function intensive care unit intensive care units Invasive mechanical ventilation IQR mechanical ventilation median men Mortality multicentre Nicotine Nicotinic receptor not differ Odds ratio on mechanical ventilation Organ failure Patient Placebo placebo-controlled placebo-controlled trial Pneumonia Primary outcome Randomized randomized trial Randomly receive receiving reduce renal replacement therapy secondary outcome Severe COVID-19 pneumonia significantly smoker stratified symptomatic patient the median the placebo group Trial two group two groups vasopressor support Ventilation ventilator-free day with COVID-19 [DOI] 10.1007/s00134-022-06721-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Traditional Vietnamese medicine Kovir capsule in patients with mild COVID-19: A double-blind randomized controlled trialRandomized Controlled Trial Published on 2022-07-012022-10-04 Journal: Phytotherapy research : PTR [Category] Coronavirus, COVID19(2023년), SARS, 임상, [키워드] adverse events clearance conducted COVID-19 decrease discharge disease double-blind double-blind study Efficacy evaluate Herbal IMPROVE in both group Mild mild COVID-19 patients outcome Patient patients PCR-confirmed Placebo placebo-controlled progression Randomized Randomized controlled trial recruited required respiratory infections Safe Safety SARS-CoV-2 severe COVID-19 significantly lower Symptom symptom resolution Symptoms the placebo group Traditional Traditional medicine Treatment Trial two groups Two patient viral clearance Viral load [DOI] 10.1002/ptr.7455 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and efficacy of favipiravir for the management of COVID-19 patients: A preliminary randomized control trialResearch article Published on 2022-07-012022-10-05 Journal: Clinical Infection in Practice [Category] 임상, 치료제, [키워드] accelerated ALT assessment AST average Bangladesh chest X-ray clinical condition COVID-19 COVID-19 patient double-blinded early stage Efficacy examined Favipiravir FVP group hematological parameter hospitalized COVID-19 patient identify improvement infections Infectious disease Lymphocyte count management neutrophil novel coronavirus disease parameter Patient patients Placebo Randomized Randomized controlled trial Result Safe Safety SARS-CoV-2 significant difference Standard of care the placebo group transaminase treated Trial viral clearance was done WBC [DOI] 10.1016/j.clinpr.2022.100145 [Article Type] Research article
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19Covid-19 예방을 위한 근육주사 AZD7442(Tixagevimab-Cilgavimab)Clinical Trial Published on 2022-06-092022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 비임상, 신약개발, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adverse event adverse events age animal models assigned AstraZeneca breath cilgavimab Combination composed conducted coronavirus coronavirus disease Coronavirus disease 2019 Critical death dose Efficacy efficacy end point end point enrolled exposure to Follow-up Human incidence increased risk intramuscular injections median Mild moderate Neutralizing antibodies neutralizing antibody occurred participant pharmacokinetic data phase 3 trial Placebo placebo group prevention primary analysis Prophylactic randomization Randomized Randomly receive Relative risk reported respiratory response to vaccination risk reduction saline placebo SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity shown single dose symptomatic COVID-19 the placebo group therapeutic effect Tixagevimab [DOI] 10.1056/NEJMoa2116620 PMC 바로가기 [Article Type] Clinical Trial